Angiotensin II receptor blocker valsartan and endothelial function in patients with chronic heart failure


Cite item

Full Text

Abstract

Role of valsartan in treatment of chronic heart failure and it's influence on endothelial function of these patients is discussed

References

  1. Агеев Ф.Т., Арутюнов Г.П. Хроническая сердечная недостаточность М., Гэотар-Медиа, 2010
  2. Минушкина Л.О., Затейщиков Д.А. Станет ли валсартан препаратом первого ряда для лечения сердечной недостаточности? Фарматека 2004; 86(8)Ж 23 - 28
  3. Максимов М.Л. Дербенцева Е.А., Дралова О.В., Стародубцев А.К., Остроумова О.Д. Применение блокатора АТ1-рецепторов ангиотензина II валсартана у пациентов с хронической сердечной недостаточностью. Сердечная недостаточность 2010; 11 (5): 301-305
  4. Максимов М.Л. Ермолаева А.С. Дралова О.В. Артериальная гипертония, ожирение, эректильная дисфункция. Какой препарат выбрать? Кардиология 2011; 7: 58-64
  5. Кукес В.Г., Семенов А.В., Сычев Д.А., Проблемы взаимодействия лекарственных средств в кардиологической практике: антигипертензивные и гиполипидемические препараты. Российский медицинский журнал 2006; 20: 1423-1428.
  6. Оганов Р.Г., Масленникова Г.Я., Шальнова С.А., Деев А.Д. Значение сердечно-сосудистых и других неинфекционных заболеваний для здоровья населения России. Профилактика заболеваний и укрепление здоровья 2002;2:3-10
  7. Фомин В.В. Блокаторы рецепторов ангиотензина II показаны большинству больных артериальной гипертензией? Системные гипертензии 2008; 1: 34-39
  8. Dzau VJ, Bernstein K., Celermajer D. et al. Pathophysiologic and therapeutic implications of tissue ACE: a consensus report. Cardiovasc Drugs Ther. 2002; 16(2): 149-160
  9. Cottone S, Vadala A, Mangano MT et al. Endothelium-derived factors in microalbuminuric and nonmicroalbuminuric essential hypertensives. Am J Hypertens 2000; 13: 172-176
  10. Delles C, Schmieder RE. Renal endothelial effects of antihypertensive therapy.Curr Opin Nephrol Hypertens 2004; 13: 489-493
  11. Remuzzi G, Weening JJ. Albuminuria as early test for vascular disease. Lancet 2005; 365: 556-557.
  12. Klingbeil AU, John S, Schneider MP et al. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003; 16 (2): 123-128.
  13. Inoue M, Fujii S, Taisei M et al. Dilation of the brachial artery in response to sublingual nitroglycerin can predict the antihypertensive effects of valsartan: a study using novel high-frequency high-frame-rate ultrasound imaging. J Cardiol 2006; 47 (1): 9-14.
  14. Ikeda F, Azuma K, Ogihara T et al. Angiotensin II type 1 receptor blocker reduces monocyte adhesion to endothelial cells in spontaneously hypertensive rats. Endocr J 2007; 54 (4): 605-612.
  15. Yamamoto E, Kataoka K., Shintaku H. et. al. Novel mechanism and role of angiotensin II induced vascular injury in hypertensive diastolic heart failure. Arterioscler Thromb Vasc Biol 2007; 27:2569-2575
  16. Su K.H., Tsai J.Y., Kou Y.R. et al. Valsartan regulates the interaction of angiotensin II type 1 receptor and endothelial nitric oxide synthase via Src/PI3K/Akt signaling. Cardiovasc Res. 2009; 82: 468-475
  17. De LasHeras N, Aragoncillo P, Maeso R. et al. AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Hypertension 1999; 34: 969-975.
  18. Gervais M, Richer C, Fornes P et al. Valsartan and coronary haemodynamics in early post-myocardial infarction in rats. Fundam Clin Pharmacol 1999;13:635-645.
  19. Higuchi T. et al. Effect of angiotensin receptor blocker valsartan on coronary microvascular flow reserve in moderately hypertensive patients with stable coronary artery disease. Microcirculation 2007; 14:805-812
  20. Richer C, Fornes P, Domergue V et al. Combined angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on survival and cardiac remodeling in chronic heart failure in rats. J Card Fail 2001;7:269-276
  21. Kuno A, Miura T, Tsuchida A, et al. Blockade of angiotensin II type 1 receptors suppressed free radical production and preserved coronary endothelial function in the rabbit heart after myocardial infarction. J CardiovascPharmacol 2002;39:49-57.
  22. Oubina MP, de Las Heras N, Vazquez-Perez S,et al. Valsartan improves fibrinolytic balance in atherosclerotic rabbits. J Hypertens 2002;20:303-310
  23. Tzemos N, Lim PO, McDonald TM. Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study. Cardiovascular Therapeutics 2009; 27: 151-158
  24. Viberti G, Wheeldon NM. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106 (6): 672-678.
  25. Katayama S, Yagi S, Yamamoto H et al. Is renoprotection by angiotensin receptor blocker dependent on blood pressure: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study. Hypertens Res 2007; 30 (6): 529-533.
  26. Watanabe S, Okura T, Kurata M et al. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension. Clin Exp Hypertens 2006; 28 (5): 451-61.
  27. Yilmaz I.M. et al. Improving proteinuria endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril vs valsartan. Blood Purif, 2007; 25: 327-335
  28. Fu CH, Yang CC, Kuo TB. Effects of different classes of antihypertensive drugs on cerebral hemodynamics in elderly hypertensive patients.Am J Hypertens 2005; 18 (12 Pt. 1): 1621-1625.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies